This invention relates to Factor VIII muteins that are covalently bound, at one or more predefined sites that are not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity, are capable of correcting human factor VIII deficiencies and have improved pharmacokinetic properties.

 
Web www.patentalert.com

< Binding molecules against SARS-coronavirus and uses thereof

> Porous materials embedded with nanospecies, methods of fabrication thereof, and methods of use thereof

> Molecules and methods for inhibiting shedding of KIM-1
~ 00566